hypgen clinician


HypGen Inc is developing a proprietary ‘platform’ technology, a differentiation agent phorbol 12-myristate 13-acetate (PMA) internally called RP-323 [Figure 1]. HypGen will be in clinical phase I/II studies for Parkinson’s disease (PD). An agreement with a University Medical Center Department of Neurology, in Atlanta Georgia, has been developed to conduct the clinical trial.